These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

366 related articles for article (PubMed ID: 15514207)

  • 1. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice.
    Verschuren L; Kleemann R; Offerman EH; Szalai AJ; Emeis SJ; Princen HM; Kooistra T
    Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):161-7. PubMed ID: 15514207
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol.
    Kooistra T; Verschuren L; de Vries-van der Weij J; Koenig W; Toet K; Princen HM; Kleemann R
    Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2322-30. PubMed ID: 16873727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice.
    Nachtigal P; Pospisilova N; Jamborova G; Pospechova K; Solichova D; Andrys C; Zdansky P; Micuda S; Semecky V
    Life Sci; 2008 Mar; 82(13-14):708-17. PubMed ID: 18289605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice.
    Zadelaar AS; Boesten LS; Jukema JW; van Vlijmen BJ; Kooistra T; Emeis JJ; Lundholm E; Camejo G; Havekes LM
    Arterioscler Thromb Vasc Biol; 2006 Nov; 26(11):2560-6. PubMed ID: 16931788
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor necrosis factor-alpha promotes atherosclerotic lesion progression in APOE*3-Leiden transgenic mice.
    Boesten LS; Zadelaar AS; van Nieuwkoop A; Gijbels MJ; de Winther MP; Havekes LM; van Vlijmen BJ
    Cardiovasc Res; 2005 Apr; 66(1):179-85. PubMed ID: 15769461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice.
    Delsing DJ; Offerman EH; van Duyvenvoorde W; van Der Boom H; de Wit EC; Gijbels MJ; van Der Laarse A; Jukema JW; Havekes LM; Princen HM
    Circulation; 2001 Apr; 103(13):1778-86. PubMed ID: 11282910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDOC and atorvastatin have potential antiinflammatory effects in vascular endothelium of apoE-/- mouse model of atherosclerosis.
    Nachtigal P; Pospisilova N; Pospechova K; Jamborova G; Kopecky M; Jaynes R; Briestensky J; Santar I; Smahelova A; Solichova D; Zdansky P; Semecky V
    Life Sci; 2006 Mar; 78(17):1983-9. PubMed ID: 16305803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice.
    Berbée JF; Wong MC; Wang Y; van der Hoorn JW; Khedoe PP; van Klinken JB; Mol IM; Hiemstra PS; Tsikas D; Romijn JA; Havekes LM; Princen HM; Rensen PC
    J Nutr Biochem; 2013 Aug; 24(8):1423-30. PubMed ID: 23337345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice.
    van Vlijmen BJ; van den Maagdenberg AM; Gijbels MJ; van der Boom H; HogenEsch H; Frants RR; Hofker MH; Havekes LM
    J Clin Invest; 1994 Apr; 93(4):1403-10. PubMed ID: 8163645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of amlodipine, atorvastatin and combination of both on advanced atherosclerotic plaque in APOE*3-Leiden transgenic mice.
    van de Poll SW; Delsing DJ; Wouter Jukema J; Princen HM; Havekes LM; Puppels GJ; van der Laarse A
    J Mol Cell Cardiol; 2003 Jan; 35(1):109-18. PubMed ID: 12623305
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overexpression of fibrinogen in ApoE*3-Leiden transgenic mice does not influence the progression of diet-induced atherosclerosis.
    Rezaee F; Gijbels MJ; Offerman EH; van der Linden M; De Maat MP; Verheijen JH
    Thromb Haemost; 2002 Aug; 88(2):329-34. PubMed ID: 12195708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Torcetrapib does not reduce atherosclerosis beyond atorvastatin and induces more proinflammatory lesions than atorvastatin.
    de Haan W; de Vries-van der Weij J; van der Hoorn JW; Gautier T; van der Hoogt CC; Westerterp M; Romijn JA; Jukema JW; Havekes LM; Princen HM; Rensen PC
    Circulation; 2008 May; 117(19):2515-22. PubMed ID: 18458167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs.
    van Vlijmen BJ; Pearce NJ; Bergö M; Staels B; Yates JW; Gribble AD; Bond BC; Hofker MH; Havekes LM; Groot PH
    Arzneimittelforschung; 1998 Apr; 48(4):396-402. PubMed ID: 9608883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atorvastatin has distinct effects on endothelial markers in different mouse models of atherosclerosis.
    Nachtigal P; Jamborova G; Pospisilova N; Pospechova K; Solichova D; Zdansky P; Semecky V
    J Pharm Pharm Sci; 2006; 9(2):222-30. PubMed ID: 16959191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging.
    Yonemura A; Momiyama Y; Fayad ZA; Ayaori M; Ohmori R; Higashi K; Kihara T; Sawada S; Iwamoto N; Ogura M; Taniguchi H; Kusuhara M; Nagata M; Nakamura H; Tamai S; Ohsuzu F
    J Am Coll Cardiol; 2005 Mar; 45(5):733-42. PubMed ID: 15734619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temporal relationships between circulating levels of CC and CXC chemokines and developing atherosclerosis in apolipoprotein E*3 Leiden mice.
    Murphy N; Bruckdorfer KR; Grimsditch DC; Overend P; Vidgeon-Hart M; Groot PH; Benson GM; Graham A
    Arterioscler Thromb Vasc Biol; 2003 Sep; 23(9):1615-20. PubMed ID: 12842836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-density lipoproteins retard the progression of atherosclerosis and favorably remodel lesions without suppressing indices of inflammation or oxidation.
    Choudhury RP; Rong JX; Trogan E; Elmalem VI; Dansky HM; Breslow JL; Witztum JL; Fallon JT; Fisher EA
    Arterioscler Thromb Vasc Biol; 2004 Oct; 24(10):1904-9. PubMed ID: 15319266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin.
    Kleemann R; Princen HM; Emeis JJ; Jukema JW; Fontijn RD; Horrevoets AJ; Kooistra T; Havekes LM
    Circulation; 2003 Sep; 108(11):1368-74. PubMed ID: 12939225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disodium ascorbyl phytostanyl phosphate reduces plasma cholesterol concentrations and atherosclerotic lesion formation in apolipoprotein E-deficient mice.
    Lukic T; Wasan KM; Zamfir D; Moghadasian MH; Pritchard PH
    Metabolism; 2003 Apr; 52(4):425-31. PubMed ID: 12701053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of diet-induced atheroma formation in transgenic mice expressing apolipoprotein E in the arterial wall.
    Shimano H; Ohsuga J; Shimada M; Namba Y; Gotoda T; Harada K; Katsuki M; Yazaki Y; Yamada N
    J Clin Invest; 1995 Feb; 95(2):469-76. PubMed ID: 7860728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.